Aridis Pharmaceuticals Inc. is a late-stage biopharmaceutical company focused on discovering and developing targeted immunotherapies using fully human monoclonal antibodies to treat life-threatening infectious diseases. Its lead product candidate, AR-301, is a fully human immunoglobulin G1 monoclonal antibody that has completed Phase III pivotal trials for lung infections caused by Staphylococcus aureus alpha-toxin and is being developed as an adjunctive therapy with standard-of-care antibiotics for hospital-acquired and ventilator-associated pneumonia. The company is also advancing AR-320, a monoclonal antibody targeting S. aureus alpha-toxin for infections from methicillin-resistant and susceptible strains; AR-501, an inhaled gallium citrate formulation in Phase 1/2a trials for chronic lung infections in cystic fibrosis patients; and AR-101, a human IgM monoclonal antibody in Phase II trials against Pseudomonas aeruginosa lipopolysaccharide serotype O11. Aridis Pharmaceuticals Inc. operates in the biotechnology sector, emphasizing novel anti-infective solutions for hospital and ventilator-related bacterial infections. Founded in 2003 and headquartered in Los Gatos, California, it remains dedicated to addressing unmet needs in infectious disease treatment.